Premier Alternatives

TILT Biotherapeutics

Helsinki, Finland · Founded 2013 · Privately Held (backing)

Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. TILT Biotherapeutics is based in Helsinki, Finland and was founded in 2013. Its last reported valuation was $100 million in Jun 2024. It has raised $82 million.

Last reported valuation
$100.2M
Oct 2026
Priced at
—
Total raised
$82.0M
Last round
—

TILT Biotherapeutics key facts

as of Oct 2026
  • Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer.
  • TILT Biotherapeutics is valued at approximately $100.2M as of Oct 2026 (last reported valuation).
  • It has raised $82.0M; the latest was Later Stage VC ($25.6M) in May 2025.
  • Notable investors include European Innovation Council, European Commission, Business Finland, Lifeline Ventures, Tesi — 14 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$100.2M

TILT Biotherapeutics's last reported valuation, Jun 2024. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of TILT Biotherapeutics with a free account
  • ·The complete investor list: 14 names
  • ·Watch TILT Biotherapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

TILT Biotherapeutics funding rounds

No rounds on record

No funding rounds for TILT Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

TILT Biotherapeutics valuation

TILT Biotherapeutics's last reported valuation was $100 million in Jun 2024. No priced round, secondary trade or fund mark has surfaced since.

TILT Biotherapeutics investors

14 investors are on record for TILT Biotherapeutics, including European Innovation Council, European Commission, Business Finland and Lifeline Ventures.

About TILT Biotherapeutics

Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves the utilization of oncolytic viruses to enhance tumor cell therapy and will be used in tumor-infiltrating lymphocytes, chimeric antigen receptors, and checkpoints, enabling researchers to inhibit antibody therapy for solid tumors to achieve similar results.

Sector
Healthcare
HQ
Helsinki, Finland
Founded
2013
Employees
27
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.